Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on March 14, 2016. The report serves to announce the company's financial results for the fiscal year ended December 31, 2015. The filing incorporates a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue
- Net Profit or Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: The filing text states that the full financial results are contained in the attached press release (Exhibit 99.1), which is not included in the input provided.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the issuance of the annual results announcement.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information is being furnished but shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K cover text.
- Confirm the company's remaining cash runway and liquidity status as of December 31, 2015.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the company's drug candidates.
- Check for any new debt financing or equity dilution events mentioned in the full press release.